Background In patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …

Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

For patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma
(SCCHN) limited therapeutic options exist. Only a subset of patients is suitable for …

Three weekly high-dose chemotherapy regimens in combination with weekly cetuximab are
the treatment of choice for patients with recurrent/metastatic (R/M) head and neck squamous …

Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …

Aim: Cetuximab was approved in 2008 for treating recurrent/metastatic (R/M) head-and-neck
squamous-cell carcinoma (HNSCC), and this study assessed the utilization of cetuximab for …

5507 Background: The majority of head and neck cancers overexpress the epidermal
growth factor receptor (EGFR), which is associated with aggressive tumor behavior and poor …

Purpose No randomized trials have been conducted to directly compare radiotherapy (RT)
with concomitant cisplatin (CDDP) versus concomitant cetuximab (CTX) as first-line …

Purpose: To evaluate feasibility, safety and outcome of cetuximab concurrent with
radiotherapy in locally advanced head− neck cancer. Materials and Methods: Between …

Aim The aims of the study are to evaluate the clinical outcomes of first-line treatment with
platinum-based chemotherapy and cetuximab in patients with relapsing/metastatic head and …